Split History
ETFs Holding ACOR »    ACOR Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as needed use and utilizes Co.'s ARCUS pulmonary delivery system. Co. also markets branded Ampyra (dalfampridine), extended release tablets, 10 mg for improving walking in people with multiple sclerosis. According to our ACOR split history records, Acorda Therapeutics has had 1 split.
ACOR split history picture
Acorda Therapeutics (ACOR) has 1 split in our ACOR split history database. The split for ACOR took place on January 04, 2021. This was a 1 for 6 reverse split, meaning for each 6 shares of ACOR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as Acorda Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ACOR split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acorda Therapeutics shares, starting with a $10,000 purchase of ACOR, presented on a split-history-adjusted basis factoring in the complete ACOR split history. ACOR split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/14/2011
End date: 04/13/2021
Start price/share: $162.78
End price/share: $4.16
Dividends collected/share: $0.00
Total return: -97.44%
Average Annual Total Return: -30.68%
Starting investment: $10,000.00
Ending investment: $255.69
Years: 10.01
Date Ratio
01/04/20211 for 6
ACOR is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ACST Split History
ACUR Split History
ADK Split History
ADMP Split History
ADMS Split History
ADPT Split History
ADRO Split History
ADXS Split History
AEMD Split History
AEZS Split History

Also explore: ACOR shares outstanding history

Aviat Networks, Inc. (AVNW)
Guardion Health Sciences, Inc. (GHSI)
China SXT Pharmaceuticals, Inc. (SXTC)
VYNE Therapeutics Inc. (VYNE)
The Sherwin-Williams Company (SHW)
Horizons US Marijuana Index ETF (HMUS)
MicroSectors FANG+ ETNs due January 8, 2038 (FNGS)
MicroSectors FANG+ Index 2X Leveraged ETNs due January 8, 2038 (FNGO)
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038 (FNGU)
Moleculin Biotech, Inc. (MBRX)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ACOR Insider Buying

ACOR Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.